Skip to content
Agentic OS
Menu

Intelligence / Healthtech / De Novo Grants / Roche Diagnostics

Approvalsnovel device granted (FDA De Novo)20 Oct 2026

Roche Diagnostics

20 Oct 2026: Novel device granted (FDA De Novo) · Elecsys HBsAg II quant II RxDx. Recorded in the openFDA device 510(k) (De Novo decisions).

View the source record

Granted
20 Oct 2026
Device
Elecsys HBsAg II quant II RxDx
Specialty
Microbiology
Product Code
SJM
Country
United States
Location
Indianapolis, IL
Submitted
2026-06-02
Reference
DEN260027
What this signal means

A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.

  1. 2 added in the 30 days to 19 Nov 2026.
  2. Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS

Find the decision makers at Roche Diagnostics

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Roche Diagnostics in our registers.

More in Microbiology

De Novo Grants

See all

Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.